Qlaris Bio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.42M

  • Investors
  • 7

Qlaris Bio General Information

Description

Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. The company's therapies use novel mechanisms of action to treat conditions related to disturbances in intraocular pressure, including glaucoma and rare pediatric diseases, enabling physicians to access novel treatment options for ophthalmic diseases.

Contact Information

Website
www.qlaris.bio
Formerly Known As
CalypsoQ
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 770 Legacy Place, 2nd Floor
  • Dedham, MA 02026
  • United States
+1 (201)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 770 Legacy Place, 2nd Floor
  • Dedham, MA 02026
  • United States
+1 (201)

Qlaris Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qlaris Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 21-Jun-2026 $6.42M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 22-Apr-2024 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 28-Aug-2019 $25M $25M Completed Startup
To view Qlaris Bio’s complete valuation and funding history, request access »

Qlaris Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Qlaris Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Qlaris Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. The company's therapies use
Drug Discovery
Dedham, MA
10 As of 2025

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qlaris Bio Competitors (1)

One of Qlaris Bio’s competitors is Alkeus Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alkeus Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

Qlaris Bio Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Qlaris Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026188153-A2 Covalent homodimer compounds of levcromakalim Pending 06-Mar-2025
WO-2026188153-A3 Covalent homodimer compounds of levcromakalim Pending 06-Mar-2025
WO-2026169878-A1 Topical fixed dosage coformulations for ocular therapy Pending 05-Feb-2025
AU-2023371655-A1 Topical ocular delivery of cromakalim Pending 04-Nov-2022
EP-4486338-A2 Topical ocular delivery of cromakalim Pending 04-Nov-2022 A61K9/0048
To view Qlaris Bio’s complete patent history, request access »

Qlaris Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qlaris Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tekla World Healthcare Fund Asset Manager
Aberdeen Investments (Scotland) Asset Manager
Canaan Partners Venture Capital Minority
Correlation Ventures Venture Capital Minority
Mayo Clinic Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Qlaris Bio FAQs

  • When was Qlaris Bio founded?

    Qlaris Bio was founded in 2019.

  • Where is Qlaris Bio headquartered?

    Qlaris Bio is headquartered in Dedham, MA.

  • What is the size of Qlaris Bio?

    Qlaris Bio has 10 total employees.

  • What industry is Qlaris Bio in?

    Qlaris Bio’s primary industry is Drug Discovery.

  • Is Qlaris Bio a private or public company?

    Qlaris Bio is a Private company.

  • What is Qlaris Bio’s current revenue?

    The current revenue for Qlaris Bio is .

  • How much funding has Qlaris Bio raised over time?

    Qlaris Bio has raised $55.5M.

  • Who are Qlaris Bio’s investors?

    Tekla World Healthcare Fund, Aberdeen Investments (Scotland), Canaan Partners, Correlation Ventures, and Mayo Clinic are 5 of 7 investors who have invested in Qlaris Bio.

  • Who are Qlaris Bio’s competitors?

    Alkeus Pharmaceuticals is a competitor of Qlaris Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process